Apr 28, 2017
These FOAs solicit competitive supplements that focus on innovative solutions to well-recognized challenges in the development of safe and effective regenerative medicine therapies. Emphasis will be given to request that address critical issues in product development relevant for regulatory submissions. Areas of focus may include improved tools, methods, standards, or applied science that support a better understanding and improved evaluation of product manufacturing, quality, safety, or effectiveness.
Eligible award mechanisms for competitive supplements are the R41/42, R43/44, U01, U54, UM1, UM2, UC4, U24, R01, R24, P50, and P41. The twelve Regenerative Medicine FOAs have published in the NIH Guide and may be accessed at the links below. Additional information about the Regenerative Medicine Innovation Project, including a set of Frequently Asked Questions, can be found at www.nih.gov/rmi.
RFA-HL-17-023 , R43 /R44 Small Business Innovation Research (SBIR) Grant - Phase I, Phase II, Phase IIB, and Fast Track
RFA-HL-17-024 , R41 /R42 Small Business Technology Transfer (STTR) Grant - Phase I, Phase II, Phase IIB, and Fast Track
RFA-HL-17-025 , U54 Specialized Center- Cooperative Agreements
RFA-HL-17-026 , UM1 Research Project with Complex Structure Cooperative Agreement
RFA-HL-17-027 , UC4 High Impact Research and Research Infrastructure - Cooperative Agreement Programs
RFA-HL-17-028 , U24 Resource-Related Research Projects – Cooperative Agreements
RFA-HL-17-029 , R01 Research Project Grant
RFA-HL-17-030 , R24 Resource-Related Research Projects
RFA-HL-17-031 , UM2 Program Project or Center with Complex Structure Cooperative Agreement
RFA-HL-17-032 , P50 Specialized Center
RFA-HL-17-033 , P41 Biotechnology Resource Grants
RFA-HL-17-034 , U01 Research Project – Cooperative Agreements